{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Shah MM"],"funding":["NCATS NIH HHS","NIAID NIH HHS","NCI NIH HHS","NIAMS NIH HHS"],"pagination":["2502-2523"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11368657"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["79(9)"],"pubmed_abstract":["<h4>Background</h4>During the COVID-19 pandemic, novel nanoparticle-based mRNA vaccines were developed. A small number of individuals developed allergic reactions to these vaccines although the mechanisms remain undefined.<h4>Methods</h4>To understand COVID-19 vaccine-mediated allergic reactions, we enrolled 19 participants who developed allergic events within 2 h of vaccination and 13 controls, nonreactors. Using standard hemolysis assays, we demonstrated that sera from allergic participants induced stronger complement activation compared to nonallergic subjects following ex vivo vaccine exposure.<h4>Results</h4>Vaccine-mediated complement activation correlated with anti-polyethelyne glycol (PEG) IgG (but not IgM) levels while anti-PEG IgE was undetectable in all subjects. Depletion of to"],"journal":["Allergy"],"pubmed_title":["Elucidating allergic reaction mechanisms in response to SARS-CoV-2 mRNA vaccination in adults."],"pmcid":["PMC11368657"],"funding_grant_id":["UL1 TR002345","P30 AR073752","U19 AI167903","U19 AI057229","U54 CA260517"],"pubmed_authors":["Heider A","Liu J","Akk A","Ren Z","Shah MM","Patterson A","Chinthrajah S","O'Hara R","Lee AS","Durham SR","Tan TJ","Kendall PL","Davis MM","Pham CTN","Chang I","Dunham D","Park H","Arunachalam PS","Boyd SD","Gibbs BF","Fulton WT","Vel MS","Pulendran B","Hourcade DE","Sindher SB","Nadeau KC","Monroy JM","Akdis CA","Fernandes A","Galli SJ","Agache I","Shamji MH","Jerath MR","Layhadi JA","Mitchell LM","Fedina A"],"additional_accession":[]},"is_claimable":false,"name":"Elucidating allergic reaction mechanisms in response to SARS-CoV-2 mRNA vaccination in adults.","description":"<h4>Background</h4>During the COVID-19 pandemic, novel nanoparticle-based mRNA vaccines were developed. A small number of individuals developed allergic reactions to these vaccines although the mechanisms remain undefined.<h4>Methods</h4>To understand COVID-19 vaccine-mediated allergic reactions, we enrolled 19 participants who developed allergic events within 2 h of vaccination and 13 controls, nonreactors. Using standard hemolysis assays, we demonstrated that sera from allergic participants induced stronger complement activation compared to nonallergic subjects following ex vivo vaccine exposure.<h4>Results</h4>Vaccine-mediated complement activation correlated with anti-polyethelyne glycol (PEG) IgG (but not IgM) levels while anti-PEG IgE was undetectable in all subjects. Depletion of to","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Sep","modification":"2026-05-29T07:02:43.689Z","creation":"2026-04-08T03:52:37.019Z"},"accession":"S-EPMC11368657","cross_references":{"pubmed":["39033312"],"doi":["10.1111/all.16231"]}}